NASDAQ : TCRT

Alaunos Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 1.95 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 4.95M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Therapeutics, Inc. was founded in 2003 and is based in Fort Lauderdale, Florida.

Details

NameAlaunos Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees1
Founded1998
CeoHolger Weis
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS98973P3091
Cusip98973P309
Cik0001107421
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Holger Weis CPAChairman of the Board and Chief Executive Officer
Ferdinand GroenewaldVice President of Finance and Corporate Secretary

Contact

Address501 E. Las Olas Blvd., Suite 300, Fort Lauderdale, Florida 33301, United States
Phone346 355 4099
Websitehttps://www.alaunos.com